jrnls.org logo
Submit

BROWSE ALL JOURNALS

Type 2 letters to search all 19 journals

SEE ALL 19 JOURNALS
Indian Journal of Pharmaceutical Education and ResearchNOW IN
Back

IJPER · Lens · Effects of Astaxanthin Supplement on Cardiovascular Health: A Systematic Review and Meta-Analysis

PDF

Review · Volume 59, Issue 3 · pp. 865–874

Effects of Astaxanthin Supplement on Cardiovascular Health: A Systematic Review and Meta-Analysis

Yongjie Liu1, Wenyue Mo2, Huaqiang Ye1, Meihua Bao3, Zhen Long4, Ruirui Kou5, Peiyao Qiao1, Ruilong Meng1, Ruizhu Chen6, Rui He1, Le Du1, Xinzheng Gao1,2

  1. 1Key Laboratory of Tropical Translational Medicine of Ministry of Education, School of Basic Medicine and Life Sciences, Hainan Medical University, Haikou, Hainan, CHINA.
  2. 2College of Life Sciences, Hainan Normal University, Haikou, Hainan, CHINA.
  3. 3Academician Workstation, Changsha Medical University, Changsha, Hunan, CHINA.
  4. 4Guilin Medical University, Guilin, Guangxi, CHINA.
  5. 5Zunyi Medical University, Zunyi, Guizhou, CHINA.
  6. 6Lingkou Central Hospital of Ding'an County, Ding'an, Hainan, CHINA.

Abstract

Background: The objective of this study was to evaluate the effects of astaxanthin intake on the cardiovascular disease-related indicators.Materials and Methods: Fives databases, including PUBMED, CNKI, WEIPU, WAN FANG and Clinical Trials were searched up to June 30, 2023. The random-effects model was used to calculate the summary risk. A total of 17 studies were included in this meta-analysis and a total of 1101 subjects' data were included in the analysis. In all included literature studies, a randomly assigned placebo group was established as the control. In the literature included, the average intervention dose of ASTX in the experimental group was 10.14 mg/day, with an average duration of administration of 68 days.Results: The overall study did not show a significant association between Astaxanthin (ASTX) and Systolic Blood Pressure (SBP) (standardized mean difference, SMD: -0.03, 95% CI: -0.22 to 0.17, p=0.771), Diastolic Blood Pressure (DBP) (SMD: -0.16, 95% CI: -0.35 to 0.03, p=0.100), the glucose concentration (SMD: -0.12, 95% CI: -0.39 to 0.15, p=0.398) and Body Mass Index (BMI) (SMD: -0.02, 95% CI: -0.22 to 0.18, p=0.821). However, the results revealed that astaxanthin can significantly reduce total cholesterol concentration (SMD: -0.20, 95% CI: -0.37 to -0.04, p=0.000), low-density lipoprotein cholesterol concentration (LDL-C) (SMD: -0.25, 95% CI: -0.41 to -0.09, p=0.003) and triglyceride concentration (SMD: -0.17, 95% CI: -0.32 to -0.01, p=0.033). Furthermore, astaxanthin could increase the concentrations of high-density lipoprotein cholesterol (HDL-C) (SMD: 0.18, 95% CI: 0.05 to 0.32, p=0.008).Conclusion: The results of this meta-analysis indicate that astaxanthin intake can significantly improve hyperlipidemia. Further studies are needed to validate these findings and investigate the potential cardiovascular benefits of astaxanthin.

Keywords: Astaxanthin; Cardiovascular Health; Efficacy; Hyperlipidemia; Meta-Analysis

The full text of this article is available as a PDF. Open the PDF.